Author

P. Abrisqueta

h-index 35 View on Semantic Scholar

We have 3 of 319 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies.

Following preclinical findings, we evaluated safimaltib (MALT1 protease inhibitor; JNJ-67856633) in relapsed/refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia in a multi-center, phase-1, dose-escalation/dose-expansion study (NCT03900598). Primary endpoints were recommended phase-2 dose (RP2D) and...

Mark Hertzberg, Che-Ah Y. Chan, S. Opat et al. · Blood Cancer Discovery · 0 citations

Clinical trial Open access Sep 2026

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

The overall response rate was 95% (95% CI 84-99; 39 of 41 patients), and the most common grade 3-4 adverse events were neutropenia and infections, while epcoritamab showed high activity in first-line treatment for follicular lymphoma.

L. Falchi, J. Vermaat, Joshua D. Brody et al. · The Lancet Haematology · 0 citations

Open access Aug 2026

Prolonged SARS-CoV-2 infection in hematologic malignancies: clinical impact, risk factors and intra-host viral evolution

Viral intra-host mutations across the entire viral genome, predominantly within the spike were detected in most patients with prolonged COVID-19, especially in those who received anti-SARS-CoV-2 mAb as sotrovimab and tixagevimab/cilgavimab and these substitutions are associated with reduced viral susceptibility.

M. Jiménez, Cristina Andrés, A. González-Sánchez et al. · Frontiers in Immunology · 0 citations